Please login to the form below

Not currently logged in
Email:
Password:

COTI signs research technology provision deal with Merck Serono

Canada-based Critical Outcome Technologies has signed a deal with German-based pharmaceutical company Merck Serono, a division of Merck KGaA.

Canada-based Critical Outcome Technologies (COTI) has signed a deal with German-based pharmaceutical company Merck Serono, a division of Merck KGaA.

The company has developed a proprietary computer platform called Chemsas,  which can identify promising chemical compounds and speed up the development time of new drugs.

COTI has focused on small-cell lung cancer (SCLC), multiple sclerosis (MS) and HIV infection, conditions which are currently underserved by the pharmaceutical market.

The tie-up with Merck Serono will identity four to six compounds which can be tested and built into cancer drugs.

Director of business development and marketing at COTI, Michael Barr, said that the public will benefit from faster drug approvals: "That's the goal that pushes us all. If we can accelerate the process, we can get drug candidates to clinical trials and to market faster.

Barr said that Merck could spend up to two years examining various chemical compounds just to identify a few which could be used in drug development. COTI says its technology can reduce the time taken to identify compounds to three to five months, while it also identifies the efficacy and toxicity of a compound to progress the compound to further testing.

Barr concluded that COTI's Chemsas program will be attractive to pharmaceutical companies needing to get new products onto the market quickly in the face of depleted pipelines and generic competition.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics